5LYNCH TJ,BELL DW,SORDELLA R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThe New England Journal of Medicine,2004. 被引量：1
6Kris M G.How today’’s developments in the treatment of non-small cell lung cancer will change tomorrow,s standards of careThe Oncologist,2005. 被引量：1
2Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742. 被引量：1
3Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98. 被引量：1
4Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214. 被引量：1
5Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137. 被引量：1
6Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544. 被引量：1
7Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753. 被引量：1
8Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465. 被引量：1
9Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2237-2246. 被引量：1
10LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003, 9:2040-1048. 被引量：1
